A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

CompletedOBSERVATIONAL

Enrollment

36,000

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

Atrial Fibrillation

Interventions

DRUG

Apixaban

Treatment for NVAF patients

DRUG

Dabigatran

Treatment for NVAF patients

DRUG

Rivaroxaban

Treatment for NVAF patients

DRUG

Warfarin

Treatment for NVAF patients